ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026
Clinical spectrum and treatment responses in.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo compare the genotype-phenotype relationships betweenchildren with PRRT2 gene variants and 16p11.2 microdeletion syndrome.
methodsA retrospective analysis was performed on clinical data from 68 patients with PRRT2 variants and 16 patients with 16p11.2 microdeletionsyndrome at the Children’s Hospital of Chongqing Medical Universitybetween February 2015 and August 2024. Genetic testing included whole-exome sequencing and copy number variation sequencing.
results(1) PRRT2 Cohort (n=68): Clinical diagnoses included benign familial infantile epilepsy (49/68), paroxysmal kinesigenic dyskinesia (4/68),infantile convulsions with paroxysmal choreoathetosis (8/68), and otherepilepsy subtypes (7/68). Genetic analysis revealed frameshift variants in 89.7% (61/68), with c.649dupC as the predominant mutation(penetrance:77.2%). Electroencephalography detected epileptiformdischarges in 45.6% of cases. Brain MRI showed nonspecific abnormalities,including widened extra-axial spaces (75%). Oxcarbazepine showed bettertherapeutic efficacy than levetiracetam. (2) 16p11.2 microdeletion cohort (n=16): This group exhibited moresevere phenotypes: The incidence of persistent status epilepticus may behigher (18.8% vs 2.9%, P=0.045, q=0.084), with 87.5% being de novovariants and 81.2% having negative family history. Compared with the PRRT2 group, these patients had significantly increased risks of congenitalheart disease, global developmental delay, and structural brainabnormalities (all P < 0.05).
conclusionPRRT2-related disorders are characterized by incompletepenetrance and benign clinical courses, whereas 16p11.2 microdeletionsyndrome manifests complex phenotypic spectra due to polygenicinvolvement, necessitating distinct diagnostic and therapeutic strategies.
Indexed as
Identifiers
41998443What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.